200 related articles for article (PubMed ID: 36787097)
1. TUBB4B is a novel therapeutic target in non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
Yang Z; Gao S; Wong CC; Liu W; Chen H; Shang H; Wu ZY; Xu L; Zhang X; Wong N; Kuang M; Yu J
J Pathol; 2023 May; 260(1):71-83. PubMed ID: 36787097
[TBL] [Abstract][Full Text] [Related]
2. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
Song Q; Zhang X; Liu W; Wei H; Liang W; Zhou Y; Ding Y; Ji F; Ho-Kwan Cheung A; Wong N; Yu J
J Hepatol; 2023 Dec; 79(6):1352-1365. PubMed ID: 37459922
[TBL] [Abstract][Full Text] [Related]
3. Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.
Di Maira G; Foglia B; Napione L; Turato C; Maggiora M; Sutti S; Novo E; Alvaro M; Autelli R; Colombatto S; Bussolino F; Carucci P; Gaia S; Rosso C; Biasiolo A; Pontisso P; Bugianesi E; Albano E; Marra F; Parola M; Cannito S
J Pathol; 2022 May; 257(1):82-95. PubMed ID: 35064579
[TBL] [Abstract][Full Text] [Related]
4. O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress.
Xu W; Zhang X; Wu JL; Fu L; Liu K; Liu D; Chen GG; Lai PB; Wong N; Yu J
J Hepatol; 2017 Aug; 67(2):310-320. PubMed ID: 28347804
[TBL] [Abstract][Full Text] [Related]
5. Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target.
Liu D; Wong CC; Fu L; Chen H; Zhao L; Li C; Zhou Y; Zhang Y; Xu W; Yang Y; Wu B; Cheng G; Lai PB; Wong N; Sung JJY; Yu J
Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669855
[TBL] [Abstract][Full Text] [Related]
6. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances.
Lau JK; Zhang X; Yu J
J Pathol; 2017 Jan; 241(1):36-44. PubMed ID: 27757953
[TBL] [Abstract][Full Text] [Related]
7. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.
Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms.
Lequoy M; Gigante E; Couty JP; Desbois-Mouthon C
Horm Mol Biol Clin Investig; 2020 Feb; 41(1):. PubMed ID: 32112699
[TBL] [Abstract][Full Text] [Related]
9. The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC.
Rusu I; Pirlog R; Chiroi P; Nutu A; Puia VR; Fetti AC; Rusu DR; Berindan-Neagoe I; Al Hajjar N
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293225
[TBL] [Abstract][Full Text] [Related]
10. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
11. Role of caveolin-1 in hepatocellular carcinoma arising from non-alcoholic fatty liver disease.
Takeda M; Sakaguchi T; Hiraide T; Shibasaki Y; Morita Y; Kikuchi H; Ikegami K; Setou M; Konno H; Takeuchi H
Cancer Sci; 2018 Aug; 109(8):2401-2411. PubMed ID: 29896915
[TBL] [Abstract][Full Text] [Related]
12. Alternative splicing: a bridge connecting NAFLD and HCC.
Xu K; Wu T; Xia P; Chen X; Yuan Y
Trends Mol Med; 2023 Oct; 29(10):859-872. PubMed ID: 37487782
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
16. METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy.
Pan Y; Chen H; Zhang X; Liu W; Ding Y; Huang D; Zhai J; Wei W; Wen J; Chen D; Zhou Y; Liang C; Wong N; Man K; Cheung AH; Wong CC; Yu J
Cell Rep Med; 2023 Aug; 4(8):101144. PubMed ID: 37586322
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
[TBL] [Abstract][Full Text] [Related]
18. Loss of KDM6B epigenetically confers resistance to lipotoxicity in nonalcoholic fatty liver disease-related HCC.
Hatano M; Akiyama Y; Shimada S; Yagi K; Akahoshi K; Itoh M; Tanabe M; Ogawa Y; Tanaka S
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37782459
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of aging in the progression of NAFLD to HCC.
He Y; Su Y; Duan C; Wang S; He W; Zhang Y; An X; He M
Ageing Res Rev; 2023 Feb; 84():101833. PubMed ID: 36565959
[TBL] [Abstract][Full Text] [Related]
20. SPARC inhibition accelerates NAFLD-associated hepatocellular carcinoma development by dysregulating hepatic lipid metabolism.
M Onorato A; Fiore E; Bayo J; Casali C; Fernandez-Tomé M; Rodríguez M; Domínguez L; Argemi J; Hidalgo F; Favre C; García M; Atorrasagasti C; Mazzolini GD
Liver Int; 2021 Jul; 41(7):1677-1693. PubMed ID: 33641248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
